Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: An Ultimate Answer To A Drug Pricing Question

This article was originally published in Scrip

Executive Summary

Last week was one of those weeks that makes you grateful that the stock markets close for the weekend. While the preparations and arrival of Pope Francis brought much of New York's Fifth Avenue and its surrounds to a standstill as Thursday wore on, it was a shame that his presence in the city could not have had the same effect on the stock markets based there.

You may also be interested in...



Stockwatch: Hopes For Fireworks But Expectations For Goldilocks

With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.

Time Is Money: Is There A Better Way To Value Asset Duration In Biopharma Deal-Making?

Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.

Stockwatch: Alexion, United Therapeutics, Intercept And "Alternative Facts"

Mid-cap biotech companies Alexion and United Therapeutics both missed fourth-quarter sales expectations and although Intercept beat analysts' estimates with $13.4m in sales, does that justify a $3bn valuation?

Topics

Related Companies

UsernamePublicRestriction

Register

SC029883

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel